Metronidazole caution in Cockayne syndrome

A warning has been added to the prescribing information for systemic metronidazole products requiring patients with Cockayne syndrome to have their liver function tested before, during and after treatment with systemic metronidazole. Monitoring should continue until liver function is within the normal ranges or until the baseline values are reached.

This change to the prescribing information follows reports of severe hepatotoxicity and acute hepatic failure in patients with Cockayne syndrome receiving systemic metronidazole. In some cases these complications occurred very rapidly after treatment initiation and had a fatal outcome.

According to the revised prescribing information, metronidazole should only be used in patients with Cockayne syndrome after careful risk-benefit assessment and only if no alternative treatment is available. Caregivers should be advised to report immediately any symptoms of potential liver injury. Treatment should be discontinued if such symptoms occur or if liver function tests become markedly elevated during treatment.

Cockayne syndrome is a rare and fatal autosomal recessive neurodegenerative disorder characterised by microcephaly, growth failure, delayed development and premature ageing.

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

MIMS Product Slides

Product overviews prepared by the MIMS team, in a handy slide format.

Click here

Slides are initiated, funded & reviewed by the companies specified.

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS Adviser

Especially created for prescribing influencers.

Request free copy

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases